Sudeep Pharma Limited (NSE:SUDEEPPHRM)
880.00
+23.75 (2.77%)
Jul 31, 2026, 3:29 PM IST
Sudeep Pharma Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 6,423 | 6,423 | 5,020 | 4,593 | 4,287 | 3,446 |
Revenue Growth | 39.84% | 27.94% | 9.30% | 7.12% | 24.41% | 4999.06% |
Gross Profit Gross Profit Growth | 4,113 | 4,113 | 3,343 | 2,917 | 2,420 | 2,070 |
Operating Income Operating Income Growth | 2,071 | 2,071 | 1,794 | 1,729 | 812.88 | 640.66 |
Net Income Net Income Growth | 1,729 | 1,729 | 1,387 | 1,332 | 623.21 | 497.99 |
Earnings Per Share EPS Growth | 15.50 | 15.50 | 12.79 | 12.28 | 5.74 | 4.59 |
EPS Growth | 26.25% | 21.23% | 4.14% | 113.89% | 25.06% | 7745.71% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Pharmaceutical, Food and Nutrition Pharmaceutical, Food and Nutrition Growth | 3,626 | 3,626 | 3,305 | 3,107 | 3,302 | 2,874 |
Specialty Ingredients Specialty Ingredients Growth | 2,796 | 2,796 | 1,715 | 1,486 | 985.88 | 572.51 |
Total Total Growth | 6,423 | 6,423 | 5,020 | 4,593 | 4,287 | 3,446 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 1,146 | 1,146 | 519.43 | 141.03 | 133.34 | 214.74 |
Total Debt Total Debt Growth | 1,504 | 1,504 | 1,376 | 787.39 | 830.83 | 847.62 |
Net Cash (Debt) Net Cash Growth | -357.77 | -357.77 | -856.1 | -646.37 | -697.49 | -632.88 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -3.21 | -3.21 | -7.89 | -5.96 | -6.43 | -5.83 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 695.53 | 695.53 | 487.27 | 656.85 | 483.95 | -26.39 |
Capital Expenditures CapEx Growth | -853.78 | -853.78 | -642.33 | -499.86 | -471.53 | -577.54 |
Free Cash Flow Free Cash Flow Growth | -158.25 | -158.25 | -155.06 | 157 | 12.42 | -603.93 |
Free Cash Flow Growth | - | - | - | 1164.05% | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 64.04% | 64.04% | 66.60% | 63.52% | 56.44% | 60.06% |
Operating Margin | 32.25% | 32.25% | 35.74% | 37.66% | 18.96% | 18.59% |
Pretax Margin | 35.51% | 35.51% | 36.42% | 38.06% | 20.05% | 19.89% |
Profit Margin | 26.92% | 26.92% | 27.63% | 29.00% | 14.54% | 14.45% |
FCF Margin | -2.46% | -2.46% | -3.09% | 3.42% | 0.29% | -17.52% |
| Fiscal Year | Current | FY 2026 |
|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 |
Dividend Per Share Dividend Per Share Growth | 1.500 | 1.500 |
Dividend Per Share Growth | 0% | - |
Dividend Yield | 0.17% | 0.25% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 56.84 | 38.71 | - | - | - | - |
Forward PE | 51.52 | 35.53 | - | - | - | - |
PS Ratio | 15.49 | 10.42 | - | - | - | - |